Annexon (ANNX) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares.
View ANNX analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12-month price objectives for Annexon's stock. Their ANNX share price forecasts range from $3.00 to $30.00. On average, they predict the company's share price to reach $14.71 in the next twelve months. This suggests a possible upside of 423.6% from the stock's current price.
View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts.

Annexon's stock was trading at $5.17 at the start of the year. Since then, ANNX shares have decreased by 45.6% and is now trading at $2.81.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ANNX earnings forecast.

Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) EPS for the quarter, hitting analysts' consensus estimates of ($0.52).

ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

(ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO.

Annexon trades on the NASDAQ under the ticker symbol "ANNX."

Annexon's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (13.29%), GMT Capital Corp (2.65%), Acadian Asset Management LLC (1.52%), Simplify Asset Management Inc. (1.23%), Geode Capital Management LLC (0.73%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Bain Capital Life Sciences Fun, Bain Capital Life Sciences Inv, Douglas Love, James E Flynn, Jennifer Lew, Michael Overdorf, Muneer A Satter, Sanjay Keswani and Ted Yednock.
View institutional ownership trends.

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANNX stock can currently be purchased for approximately $2.81.

Annexon (NASDAQ:ANNX) has a market capitalization of $149.17 million. The company earns $-141,950,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

The official website for the company is www.annexonbio.com. The company can be reached via phone at 650-822-5500, via email at swheeler@wheelhouselsa.com, or via fax at 650-636-9773.